Literature DB >> 3507226

Determination of plasma cytidine deaminase activity by HPLC.

D A Richards1, R A Sherwood, D Ndebele, B F Rocks.   

Abstract

Cytidine deaminase is an enzyme of nucleic acid metabolism, the measurement of which has been proposed as a useful test for the early detection of pre-eclamptic toxaemia in pregnancy. The enzyme converts the nucleoside cytidine to uridine, with the release of ammonia, and it is the measurement of this latter compound that forms the basis of the conventional methods for the assay of cytidine deaminase. The low activity of the enzyme requires long incubation times, which in turn increase the possibility of contamination by exogenous ammonia. We have developed a new method for determining cytidine deaminase activity, utilising high performance liquid chromatography to measure the production of uridine. This method uses much shorter incubation times and is unaffected by ammonia contamination. This paper describes the development of the method and its comparison with the established assay. The relative merits of each are discussed. Finally, the adaptation of incubation and chromatographic conditions, in order to measure other enzymes of nucleic acid metabolism which are of clinical interest, is briefly mentioned.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3507226     DOI: 10.1002/bmc.1130020404

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  6 in total

1.  Surface enhanced Raman detection of the colon cancer biomarker cytidine by using magnetized nanoparticles of the type Fe3O4/Au/Ag.

Authors:  Yuan Xiang; Hanru Yang; Xiaoyu Guo; Yiping Wu; Ye Ying; Ying Wen; Haifeng Yang
Journal:  Mikrochim Acta       Date:  2018-02-26       Impact factor: 5.833

2.  Novel PET probes specific for deoxycytidine kinase.

Authors:  Chengyi J Shu; Dean O Campbell; Jason T Lee; Andrew Q Tran; Jordan C Wengrod; Owen N Witte; Michael E Phelps; Nagichettiar Satyamurthy; Johannes Czernin; Caius G Radu
Journal:  J Nucl Med       Date:  2010-06-16       Impact factor: 10.057

3.  Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.

Authors:  Reda Z Mahfouz; Ania Jankowska; Quteba Ebrahem; Xiaorong Gu; Valeria Visconte; Ali Tabarroki; Pramod Terse; Joseph Covey; Kenneth Chan; Yonghua Ling; Kory J Engelke; Mikkael A Sekeres; Ramon Tiu; Jaroslaw Maciejewski; Tomas Radivoyevitch; Yogen Saunthararajah
Journal:  Clin Cancer Res       Date:  2013-01-03       Impact factor: 12.531

4.  A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer.

Authors:  Davendra Sohal; Smitha Krishnamurthi; Rita Tohme; Xiaorong Gu; Daniel Lindner; Terry H Landowski; John Pink; Tomas Radivoyevitch; Sherry Fada; Zhenghong Lee; Dale Shepard; Alok Khorana; Yogen Saunthararajah
Journal:  Am J Cancer Res       Date:  2020-09-01       Impact factor: 6.166

5.  An enzymatic assay for high-throughput screening of cytidine-producing microbial strains.

Authors:  Huina Dong; Yongfei Liu; Xin Zu; Ning Li; Feiran Li; Dawei Zhang
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

6.  High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects.

Authors:  Quteba Ebrahem; Reda Z Mahfouz; Kwok Peng Ng; Yogen Saunthararajah
Journal:  Oncotarget       Date:  2012-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.